Polianta LTD Blueprint Medicines Corp Transaction History

Polianta LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 19, 2021	SELL	$80.98 - $109.47 $1.15 Million - $1.55 Million	-14,200 Closed	0 $0
Q2 2021 Jul 06, 2021	BUY	$82.78 - $101.0 $182,116 - $222,200	2,200 Added 18.33%	14,200 $1.25 Million
Q1 2021 Apr 14, 2021	BUY	$90.71 - $108.28 $126,993 - $151,592	1,400 Added 13.21%	12,000 $1.17 Million
Q4 2020 Jan 13, 2021	BUY	$92.08 - $124.48 $976,048 - $1.32 Million	10,600 New	10,600 $1.19 Million
Q3 2019 Oct 09, 2019	SELL	$72.9 - $101.41 $998,730 - $1.39 Million	-13,700 Closed	0 $0
Q2 2019 Jul 17, 2019	BUY	$73.54 - $97.8 $1.01 Million - $1.34 Million	13,700 New	13,700 $1.29 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Polianta LTD, based on Form 13F filings with the SEC.

Stay updated on Polianta LTD with notifications on news.